NSCLC, Stage IIIA Clinical Trial
— PROLUNGOfficial title:
Towards Better Therapy for Resectable Lung Cancer: Metabolomics Predict Therapy Response
Verified date | December 2023 |
Source | Hasselt University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Complete resection is the mainstay of treatment for stage I-IIIA resectable non-small cell lung cancer (NSCLC). However rates of recurrence of disease are high, with five-year survival rates ranging between 73% (stage IA) and 24% (stage IIIA). Therefore, a prognostic biological marker that stratifies between NSCLC patients whom surgery cures versus patients in whom surgery would be futile due to early disease relapse after surgery is eagerly awaited. The primary objective of this prospective study is to establish a prognostic marker of early disease progression after complete surgical resection in patients with stages I to IIIA NSCLC. For this purpose the investigator will compare the metabolic profile with disease progression or death within one year after complete surgical resection to the patients with a progression free survival. Furthermore the investigator will evaluate the changes in the metabolic profile after surgery and if changes in this metabolic profile over time can predict disease recurrence before it becomes clinically apparent.
Status | Completed |
Enrollment | 160 |
Est. completion date | December 31, 2022 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Patients with a stage I-IIIA NSCLC tumor, eligible to undergo surgery 2. Signed written informed consent Exclusion Criteria: 1. No fasting starting from 22:00 h the day prior to blood sampling 2. Medication intake in the morning of the blood sampling 3. Non-controlled diabetes 4. History of cancer during the past 5 years 5. Treatment for cancer during the past 5 years |
Country | Name | City | State |
---|---|---|---|
Belgium | OLV ziekenhuis Aalst | Aalst | |
Belgium | Ziekenhuis Oost-Limburg | Genk | |
Belgium | UZ Gent | Gent | |
Belgium | AZ Delta | Roeselare |
Lead Sponsor | Collaborator |
---|---|
Hasselt University | Ziekenhuis Oost-Limburg |
Belgium,
Beger RD, Dunn W, Schmidt MA, Gross SS, Kirwan JA, Cascante M, Brennan L, Wishart DS, Oresic M, Hankemeier T, Broadhurst DI, Lane AN, Suhre K, Kastenmuller G, Sumner SJ, Thiele I, Fiehn O, Kaddurah-Daouk R; for "Precision Medicine and Pharmacometabolomics Task Group"-Metabolomics Society Initiative. Metabolomics enables precision medicine: "A White Paper, Community Perspective". Metabolomics. 2016;12(10):149. doi: 10.1007/s11306-016-1094-6. Epub 2016 Sep 2. — View Citation
Beger RD. A review of applications of metabolomics in cancer. Metabolites. 2013 Jul 5;3(3):552-74. doi: 10.3390/metabo3030552. — View Citation
Louis E, Adriaensens P, Guedens W, Bigirumurame T, Baeten K, Vanhove K, Vandeurzen K, Darquennes K, Vansteenkiste J, Dooms C, Shkedy Z, Mesotten L, Thomeer M. Detection of Lung Cancer through Metabolic Changes Measured in Blood Plasma. J Thorac Oncol. 201 — View Citation
Louis E, Adriaensens P, Guedens W, Vanhove K, Vandeurzen K, Darquennes K, Vansteenkiste J, Dooms C, de Jonge E, Thomeer M, Mesotten L. Metabolic phenotyping of human blood plasma: a powerful tool to discriminate between cancer types? Ann Oncol. 2016 Jan;2 — View Citation
Louis E, Cantrelle FX, Mesotten L, Reekmans G, Bervoets L, Vanhove K, Thomeer M, Lippens G, Adriaensens P. Metabolic phenotyping of human plasma by 1 H-NMR at high and medium magnetic field strengths: a case study for lung cancer. Magn Reson Chem. 2017 Aug;55(8):706-713. doi: 10.1002/mrc.4577. Epub 2017 Feb 27. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The metabolic profile in plasma measured by Nuclear Magnetic Resonance (NMR) | The metabolic profile in plasma measured by Nuclear Magnetic Resonance (NMR) spectroscopy predicts disease disease recurrence within one year after surgical resection. | baseline | |
Secondary | Change in the metabolic profile in plasma measured by Nuclear Magnetic Resonance (NMR) | The degree of change in the metabolic profile in plasma before and after surgery correlates with the risk for early disease recurrence. | screening, day 1, week 1, week 4, week 6, week 12, week 52 | |
Secondary | Change in ctDNA mutations in plasma | The degree of change in ctDNA mutations in plasma before and after surgery correlates with the risk for early disease recurrence. | day 1, week 12, week 52 | |
Secondary | Correlation between presence or absence Hotspot mutations and the metabolic profile in plasma | A specific metabolic profile in plasma measured by Nuclear Magnetic Resonance (NMR) spectroscopy correlates with the presence of absence of certain ctDNA mutations in plasma | day 1, week 12, week 52 | |
Secondary | Metabolic profile of the primary tumor | The metabolic profile of the primary tumor correlates with the metabolic profile in plasma | day 1 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05157776 -
A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations
|
Phase 3 | |
Recruiting |
NCT04205552 -
Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients
|
Phase 2 | |
Withdrawn |
NCT03628144 -
Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT04865250 -
Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC
|
Phase 2 | |
Active, not recruiting |
NCT01470716 -
Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations
|
Phase 2 |